The Supreme Court will take a closer look at whether states should be allowed to ban the sale of doctors' prescription data to drug companies, the Wall Street Journal reports. The ruling would affect how pharma companies hone their marketing. Some data companies such as IMS Health Inc. collect information from pharmacies on which drugs physicians prescribe and how often. Drug makers buy the data to craft marketing pitches and see which salespeople perform best. Vermont is one state that has banned the practice, saying data-mining companies may not sell the Rx information for marketing purposes and drug makers may not use it unless the prescribing doctors approves. Article